Close Menu
    Facebook LinkedIn YouTube Instagram X (Twitter)
    Blue Tech Wave Media
    Facebook LinkedIn YouTube Instagram X (Twitter)
    • Home
    • Leadership Alliance
    • Exclusives
    • Internet Governance
      • Regulation
      • Governance Bodies
      • Emerging Tech
    • IT Infrastructure
      • Networking
      • Cloud
      • Data Centres
    • Company Stories
      • Profiles
      • Startups
      • Tech Titans
      • Partner Content
    • Others
      • Fintech
        • Blockchain
        • Payments
        • Regulation
      • Tech Trends
        • AI
        • AR/VR
        • IoT
      • Video / Podcast
    Blue Tech Wave Media
    Home » Tempus AI’s IPO: investor confidence in genomics diagnostics
    IPO
    IPO
    IT Infrastructure

    Tempus AI’s IPO: investor confidence in genomics diagnostics

    By Sissy LiJune 14, 2024No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email
    • SoftBank Group backed TempusAI’s public offering, at $37 per share, will begin trading on Nasdaq Global Select on Friday.
    • The company specializes in genomic diagnostics, offering tests in oncology, neuropsychiatry, radiology, and cardiology to clinicians and hospitals.

    OUR TAKE
    Tempus AI’s IPO at $37, with $410.7 million subscribed, shows investors are confident in the company’s potential despite its lack of profitability.

    –Sissy Li, BTW media

    What happened

    Tempus AI, backed by SoftBank Group, priced its U.S. initial public offering (IPO) at $37 per share, raising $410.7 million. This valuation, at the upper end of its targeted range of $35 to $37 per share, values the company at approximately $6.10 billion. Led by Groupon co-founder Eric Lefkofsky, Tempus AI is venturing into the public market despite its lack of profitability, a move that will scrutinise investor appetite.

    The company specialises in genomics diagnostics, offering tests in oncology, neuropsychiatry, radiology, and cardiology to clinicians and hospitals. Its shares are set to commence trading on the Nasdaq Global Select Market. The successful pricing of its IPO suggests investor confidence in the potential of Tempus AI’s technology and its ability to capitalise on the growing demand for genomic testing in various medical fields.

    Also read: Interlink Telecom Q1 profits soar 113%, subsidiary BLUE’s IPO approved

    Also read: Klarna enters major partnership with Uber ahead of anticipated IPO

    Why this is important

    TempusAI, which uses AI to process medical data, posted a net loss of $266 million on $532 million in revenue last year. The company has said in the filing that Tempus sells “smart diagnostics” as a selling point, using AI technology to help patients find the most suitable treatment plan by collecting and analyzing clinical and genomic data in large quantities.

    Capital infusion

    By raising $410.7 million through its IPO, Tempus AI gains substantial capital to fuel its expansion plans, invest in research and development, and further develop its product offerings. This influx of capital is crucial for scaling operations and staying competitive in the rapidly evolving healthcare industry.

    Industry impact

    Tempus AI’s focus on genomics diagnostics has the potential to revolutionise healthcare by enabling personalised treatment plans and improving patient outcomes. Its IPO highlights the increasing importance of genomic testing in various medical fields, including oncology, neuropsychiatry, radiology, and cardiology.

    Market validation

    The successful pricing of its IPO indicates investor confidence in Tempus AI’s business model and growth potential, despite its lack of profitability. It suggests that there is significant market interest in companies specialising in genomics diagnostics and healthcare technology.

    Eric Lefkofsky smart diagnostics SoftBank Group Tempus AI
    Sissy Li

    Sissy Li, a news reporter at BTW media dedicated in Fintech and Blockchain. She graduated from Macau University of Technology and Science. Send tips to s.li@btw.media.

    Related Posts

    Cloud Innovation calls for AFRINIC wind-up after ‘impossible’ election standards

    July 11, 2025

    Fimnet: Enabling Kenya’s Digital Growth

    July 11, 2025

    CoLi Link Ghana Limited: Pioneering connectivity

    July 11, 2025
    Add A Comment
    Leave A Reply Cancel Reply

    CATEGORIES
    Archives
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • September 2023
    • August 2023
    • July 2023

    Blue Tech Wave (BTW.Media) is a future-facing tech media brand delivering sharp insights, trendspotting, and bold storytelling across digital, social, and video. We translate complexity into clarity—so you’re always ahead of the curve.

    BTW
    • About BTW
    • Contact Us
    • Join Our Team
    TERMS
    • Privacy Policy
    • Cookie Policy
    • Terms of Use
    Facebook X (Twitter) Instagram YouTube LinkedIn

    Type above and press Enter to search. Press Esc to cancel.